ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Among the four subgroups with CML-CP evaluated by Sanger sequencing, patients with a single T315I mutation had the highest 3-year cumulative incidences of achieving MCyR (85.3%), CCyR (76.0%), MMR (68.7%), MR4.0 (59.3%), and MR4.5 (54.7%); those with no BCR-ABL1 mutation had the lowest cumulative incidences of MCyR (59.1%), CCyR (50.0%), MMR (9.1%), MR4.0 (4.5%), and MR4.5 (0) (all P values among the four subgroups < 0.0001; Fig. 4A).